GLP-1 heart health is a topic that gets more interesting the closer you look. For a while, most of the conversation came down to one question: do these drugs protect the heart simply because people lose weight? That's a fair place to start, but it doesn't settle much. To understand what GLP-1 medicines might do for your cardiovascular system, you need to look at mechanisms and at the numbers doctors can actually measure, like blood pressure, resting heart rate, lipids, and inflammation markers. We touched on the weight debate in an earlier PeptPro post, and this one picks up from there.
Blood pressure, heart rate, lipids, and inflammation markers show part of the picture of GLP-1 heart health. Here is what they reveal, and what they don't.
Why the question moved from weight to mechanisms
Weight is a convenient stand-in, but a blunt one. What matters most to patients are clinical outcomes: heart attack, stroke, and death from cardiovascular causes. Markers like systolic blood pressure or LDL cholesterol are easier to measure and often shift sooner. Still, a better number on a lab report doesn't guarantee fewer events down the road.
The strongest outcome evidence so far comes from the SELECT trial. It enrolled adults with overweight or obesity and established cardiovascular disease, with or without diabetes, and randomized them to weekly semaglutide 2.4 mg or placebo. The primary endpoint was major adverse cardiovascular events (MACE), a combined measure of cardiovascular death, heart attack, and stroke. The results appeared in the New England Journal of Medicine in 2023. Read the paper itself for the exact effect size, since press summaries often simplify it.
Regulatory labels are the next piece of the puzzle. Approved uses differ between countries and can change over time, so check the current prescribing information where you live rather than relying on a headline.
Track your labs and see how your protocol moves your biomarkers.
Track it in the app
